英国根据美国新的贸易协议,降低药物回扣,并增加国民保健制度用于促进生命科学的开支。 The UK lowers drug rebates and boosts NHS spending to boost life sciences under new US trade deal.

根据与美国达成的取消对英国药品出口关税的新贸易协议,英国将在2026年将其药物回扣率从22.9%降至14.5%。 The UK will cut its drug rebate rate from 22.9% to 14.5% in 2026 under a new trade deal with the US that eliminates tariffs on British pharmaceutical exports. 作为交换,国民保健制度将把新药品的支出门槛提高25%,估计到2029年每年耗资10亿英镑。 In exchange, the NHS will raise its spending threshold for new medicines by 25%, costing an estimated £1 billion annually by 2029. 政府说,降低折扣,加上药品价格下跌,将有助于抵消成本,增加对临床试验和及早获得新治疗的投资。 The government says lower rebates, combined with falling drug prices, will help offset costs and boost investment in clinical trials and early access to new treatments. 工业领导人欢迎这一举动,认为这是提高英国生命科学竞争力的一个步骤,尽管付款率仍然高于类似国家。 Industry leaders welcome the move as a step toward improving the UK’s competitiveness in life sciences, though payment rates remain higher than in similar countries.